Frazier Life Sciences Management, L.P. Allakos Inc. Transaction History

Frazier Life Sciences Management, L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 15, 2023	SELL	$4.3 - $8.27 $15.8 Million - $30.4 Million	-3,679,316 Reduced 76.78%	1,112,684 $4.95 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $6.12 $14.5 Million - $29.3 Million	4,792,000 New	4,792,000 $29.3 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.